Company intelligence / Profile preview

Jiangsu Coast Pharmaceutical Co., Ltd.

Ownership: Private
Development stage: Commercial

Overview

Jiangsu Coast Pharmaceutical Co., Ltd. develops and manufactures generic pharmaceuticals, with a focus on conducting bioequivalence studies to support regulatory approval in China. Recent clinical trials include comparative pharmacokinetic and safety studies for generic versions of crisaborole ointment and aprepitant capsules against their respective branded reference products. There are no indications that the company has proprietary new molecular entities or platform technologies under development.

Therapeutic areas: OncologyDermatology
Modalities: Small moleculesGenerics/Generic formulations
Industry: Biotech

Drug pipeline

2 assets

silver protein dodecyl sulfonate

Preclinical

1 more asset in the full pipeline.

Partnerships

No major pharmaceutical or biotech partnerships disclosed.

Beyond the preview

Go deeper on Jiangsu Coast Pharmaceutical Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jiangsu Coast Pharmaceutical Co., Ltd..